March 2025
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis
FDA Approves First Treatment for Macular Telangiectasia Type 2 (MacTel)
ENCELTO, revakinagene taroretcel-lwey, MacTel, FDA approval, encapsulated cell therapy, ciliary neurotrophic factor (CNTF)
In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
United States Food and Drug Administration, Makary, Vaccines, Ethics, Advisory Committees
Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO
Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery
Makary Sails Through Senate Confirmation Hearing for FDA Commissioner
Martin Makary, FDA, Senate confirmation hearing, vaccine advisory committee, drug reviews, ethics, staffing changes
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
UPDATE: DOGE quietly decreases savings estimate for 30 terminated FDA leases
Financial savings, United States Food and Drug Administration, DOGE, Estimated, leases, terminated – RoleStatus, St. Louis, DOGE ‘s
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
United States National Institutes of Health, Judge, injunction, implementing